PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D growth 50-75% of AVXL's 11.10%. Bruce Berkowitz would examine spending effectiveness.
58.15%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth above 1.5x AVXL's 5.30%. Michael Burry would check for inefficiency.
20.40%
Total costs growth above 1.5x AVXL's 5.30%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-20.82%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth less than half of AVXL's 202.83%. David Dodd would verify if advantage is sustainable.
-19.78%
Pre-tax income decline while AVXL shows 10.43% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Net income decline while AVXL shows 10.36% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth 1.25-1.5x AVXL's 8.33%. Bruce Berkowitz would examine sustainability.
12.20%
Diluted EPS growth 1.25-1.5x AVXL's 8.33%. Bruce Berkowitz would examine sustainability.
35.62%
Share count reduction below 50% of AVXL's 1.29%. Michael Burry would check for concerns.
35.62%
Diluted share reduction below 50% of AVXL's 1.29%. Michael Burry would check for concerns.